Novatarg is a bispecific antibody targeting CD20 and Fas. It is intended for inducing Fas-mediated apoptosis only in cells expressing CD20, which is an established target antigen for antibody-based immunotherapy in cancer (such as lymphoma) and B-cell-mediated autoimmune disease (86, 87). Here, FAS is linked to lymphoma.